SI1755647T1 - Zdravljenje amiotrofiäśne lateralne skleroze - Google Patents

Zdravljenje amiotrofiäśne lateralne skleroze

Info

Publication number
SI1755647T1
SI1755647T1 SI200531098T SI200531098T SI1755647T1 SI 1755647 T1 SI1755647 T1 SI 1755647T1 SI 200531098 T SI200531098 T SI 200531098T SI 200531098 T SI200531098 T SI 200531098T SI 1755647 T1 SI1755647 T1 SI 1755647T1
Authority
SI
Slovenia
Prior art keywords
treatment
lateral sclerosis
amyotrophic lateral
relates
als
Prior art date
Application number
SI200531098T
Other languages
English (en)
Inventor
Peter Carmeliet
Original Assignee
Vib Vzw
Life Sciences Res Partners Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Life Sciences Res Partners Vzw filed Critical Vib Vzw
Publication of SI1755647T1 publication Critical patent/SI1755647T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Automatic Cycles, And Cycles In General (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI200531098T 2004-05-27 2005-05-27 Zdravljenje amiotrofiäśne lateralne skleroze SI1755647T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04102334 2004-05-27
EP05747975A EP1755647B1 (en) 2004-05-27 2005-05-27 Treatment of amyotrophic lateral sclerosis
PCT/EP2005/052430 WO2005117946A1 (en) 2004-05-27 2005-05-27 Treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
SI1755647T1 true SI1755647T1 (sl) 2011-01-31

Family

ID=34968798

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200531098T SI1755647T1 (sl) 2004-05-27 2005-05-27 Zdravljenje amiotrofiäśne lateralne skleroze

Country Status (17)

Country Link
US (2) US7687463B2 (sl)
EP (1) EP1755647B1 (sl)
JP (2) JP5537770B2 (sl)
AT (1) ATE478678T1 (sl)
AU (1) AU2005249234B2 (sl)
CA (1) CA2568158A1 (sl)
CY (1) CY1111654T1 (sl)
DE (1) DE602005023155D1 (sl)
DK (1) DK1755647T3 (sl)
ES (1) ES2351804T3 (sl)
HR (1) HRP20100555T1 (sl)
ME (1) ME01870B (sl)
PL (1) PL1755647T3 (sl)
PT (1) PT1755647E (sl)
RS (1) RS51481B (sl)
SI (1) SI1755647T1 (sl)
WO (1) WO2005117946A1 (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076620A2 (en) * 2000-04-12 2001-10-18 Vlaams Interuniversitair Instituut Voor Biotecnologie Vzw Use of vegf and homologues to treat neuron disorders
PT1755647E (pt) 2004-05-27 2010-09-29 Vzw Vib Tratamento da esclerose lateral amiotrófica
US20130274235A1 (en) * 2010-10-08 2013-10-17 The General Hospital Corporation Treatment of motor neuron disease
AU2013299832B2 (en) 2012-08-07 2016-11-24 Children's Medical Center Corporation Methods to treat neurodegenerative diseases
US20140155816A1 (en) * 2012-10-09 2014-06-05 Eu Sol Biotech Co., Ltd. Method for treating brain injury or stroke
EP3052191B1 (en) * 2013-10-01 2020-03-18 Kadimastem Ltd. Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of amyotrophic lateral sclerosis (als)
KR20230138815A (ko) * 2022-03-24 2023-10-05 주식회사 아이엔테라퓨틱스 인비보 패치 클램프 기법을 이용한 전기생리학적 약효 평가법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
WO2004031390A1 (en) * 2002-10-04 2004-04-15 Oxford Biomedica (Uk) Limited Vector system
CZ250499A3 (cs) 1997-01-17 1999-11-17 Rhone-Poulenc Rorer S. A. Použití nukleové kyseliny k indukci inervace svalů a růstu axonů motorických neuronů
KR20010034576A (ko) 1998-03-13 2001-04-25 벤슨 로버트 에이치. 혈관 내피 성장 인자 2
EP1064382B1 (en) * 1998-03-17 2008-08-20 Genentech, Inc. Polypeptides homologous to vegf and bmp1
JP2002526083A (ja) 1998-09-23 2002-08-20 オックスフォード バイオメディカ（ユーケイ）リミテッド ポリヌクレオチド構築物およびその使用
US7125856B1 (en) * 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
AU782819B2 (en) 1999-04-15 2005-09-01 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
WO2001076620A2 (en) * 2000-04-12 2001-10-18 Vlaams Interuniversitair Instituut Voor Biotecnologie Vzw Use of vegf and homologues to treat neuron disorders
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
PT1755647E (pt) 2004-05-27 2010-09-29 Vzw Vib Tratamento da esclerose lateral amiotrófica

Also Published As

Publication number Publication date
US7687463B2 (en) 2010-03-30
AU2005249234B2 (en) 2010-08-05
ES2351804T3 (es) 2011-02-10
PT1755647E (pt) 2010-09-29
ATE478678T1 (de) 2010-09-15
US20080279906A1 (en) 2008-11-13
HRP20100555T1 (hr) 2011-01-31
EP1755647B1 (en) 2010-08-25
JP2012111774A (ja) 2012-06-14
DK1755647T3 (da) 2010-10-11
ME01870B (me) 2011-04-30
US7863246B2 (en) 2011-01-04
PL1755647T3 (pl) 2011-01-31
EP1755647A1 (en) 2007-02-28
JP2008500312A (ja) 2008-01-10
US20100152116A1 (en) 2010-06-17
CY1111654T1 (el) 2015-10-07
JP5537770B2 (ja) 2014-07-02
DE602005023155D1 (de) 2010-10-07
CA2568158A1 (en) 2005-12-15
WO2005117946A1 (en) 2005-12-15
RS51481B (en) 2011-04-30
AU2005249234A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
CY1111654T1 (el) Θεραπευτικη αγωγη πλαγιας μυατροφικης σκληρυνσης
ZA200604322B (en) Method to reduce odor of excreta from companion animals
ECSP11011173A (es) Agentes inductores de apoptosis para el tratamiento de cancer y enfermedades inmunes y autoinmunes
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
MX2009006066A (es) Tratamiento de cerdos con el antigeno pcv.
ECSP12012020A (es) Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes
ECSP11011554A (es) Agentes inductores de apoptosis para el tratamiento de cáncer y enfermedades inmunes y autoinmunes.
EP1951892A4 (en) ANTIBODY TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
DE602004016729D1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
PT1715755E (pt) Utilização de bactérias vivas para promover o crescimento em animais
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
ATE398398T1 (de) Nahrungsmittelzusatz
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
WO2006053788A3 (en) Alterations in seborrheic keratoses and their applications
MY147152A (en) Anti-foot-and-mouth disease virus agent for animal belonging to family suidae or sheep, and method for prevention or treatment of foot-and-mouth disease in animal belonging to family suidae or sheep
UA92593C2 (ru) Лечение мастита энрофлоксацином
WO2007065024A3 (en) Composition and use of phyto-percolate for treatment of disease
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
EP1909784A4 (en) CYSTEIN PROTEASE HEMMER OF THE PAPAIN FAMILY FOR THE TREATMENT OF PARASITIC ILLNESSES
NL1025844A1 (nl) Benzopyranverbindingen voor gebruik bij de behandeling en preventie van ontstekingsgerelateerde aandoeningen.
WO2008027880A3 (en) Strontium-based treatment of otosclerosis
FR2867026B1 (fr) Composition phytosanitaire destinee au traitement antifongique des cultures.
UA92731C2 (ru) Лекарственное средство для гигиеничной обработки уха
FR2857364B1 (fr) Dosage des acides techoiques des bacteries gram+